CD8A and prostate cancer: Murine models of castrate-resistant prostate cancer refractory to oxaliplatin treatment have demonstrated an increased presence of IgA+ Plasma cells that induce exhaustion of CD8+ T cells through PDL1 expression, as well as TGF-β and IL-10 production, a true regulatory suppressive plasma cell phenotype (72).